Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVACT: Preventive Reversal of VKA in Head Trauma
NCT01961804Phase 3Terminated
- Sponsor
- Centre Hospitalier Universitaire d'Angers
- Start
- Mar 2014
- Primary completion
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of balfaxar in intracranial hemorrhage (ICH) (2 arms), sponsored by Centre Hospitalier Universitaire d'Angers. Primary endpoint: Percentage of intracranial bleeding diagnosed in CT scan at 24 hours. Started Mar 2014; status: terminated.
02
Drugs
balfaxar
03
Conditions
intracranial hemorrhage (ICH)
Beyond the preview
Go deeper on NCT01961804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01961804.